Zealand Pharma expands management team

Danish biopharmaceutical firm makes three senior appointments

Danish biopharmaceutical company Zealand Pharma has appointed Christian Grondahl as chief scientific officer, Mats Blom as chief financial officer and John Hyttel as senior vice president for operations.

"Together they bring a wealth of experience, energy and skills to Zealand Pharma as we continue to advance our growth strategy," said David Horn Solomon, chief executive of Zealand Pharma.

Grondahl starts on 1 April, joining the firm from Novo Nordisk, where until recently he was corporate vice president for strategic alliances.

Blom, who joined the company earlier this month, was cfo of Swedish Orphan International, which recently merged with Biovitrum to form Swedish Orphan-Biovitrum of Stockholm.

Hyttel, who became senior vice president for operations on 1 March, founded Zealand Pharma in 1998. He worked for H Lundbeck for 30 years prior to joining Zealand.

Zealand's most advanced project, Lixisenatide (ZP10/AVE0010), a GLP-1 agonist for the treatment of Type II diabetes has been out licensed to Sanofi-Aventis of France. Sanofi-Aventis is completing 9 Phase III trials with first results to be released in June. Sanofi-Aventis is also commercialising a Lantus-Lixisenatide combination product for the treatment of Type II diabetes that has completed Phase I clinical studies. Submission of IND/MAA for Lixisenatide is expected in 2011.

You may also like

Research & Development

Weight loss drugs such as Ozempic may prevent stroke and reduce brain injury related complications

Three studies presented at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether
Research & Development

Amphista Therapeutics reaches research milestone and triggers a milestone payment from Merck

Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue degraders for oncology and immunology indications
Manufacturing

Precision under pressure

Why pharma manufacturing needs a harder look at weight control
Research & Development

Qureight analyses of Insilico Medicine’s Phase IIa rentosertib data support preliminary efficacy results and future trial expansion

Qureight’s deep-learning image biomarkers and clinical data analytics platform used to analyse enrolled idiopathic pulmonary fibrosis (IPF) patient data, supporting efficacy outcome and expansion to larger global patient studies
Research & Development

Strategic investment by Bain Capital, Kohlberg and Mubadala fuels PCI Pharma Services’ expansion

This financial injection is expected to cement PCI’s position in the CDMO arena
Manufacturing

WLS introduces PR-12 and PR-24 plunger rod insertion and labelling systems

By improving reliability and streamlining production, the PR-12 and PR-24 help pharmaceutical manufacturers and contract packers protect product quality and reduce waste while maximising operational efficiencies
Manufacturing

Isopod Rapid Cleanrooms – the elite modular systems saving your host building from unwanted modifications

Suffolk-based cleanroom construction specialists the Guardtech Group have the perfect modular solution for clients who need to keep their host rooms intact
Subscribe now